AIM ImmunoTech Inc.
AIM · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.02 | 0.34 | 0.19 |
| FCF Yield | -133.05% | -102.22% | -109.97% | -33.52% |
| EV / EBITDA | -0.75 | -0.58 | 0.57 | -0.63 |
| Quality | ||||
| ROIC | -1,221.25% | -291.42% | -50.69% | -33.01% |
| Gross Margin | 81.76% | 79.21% | 400.71% | -529.63% |
| Cash Conversion Ratio | 0.86 | 0.73 | 0.83 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.43% | 14.38% | -4.72% | -1.20% |
| Free Cash Flow Growth | 31.79% | -33.41% | -12.20% | -33.16% |
| Safety | ||||
| Net Debt / EBITDA | -0.08 | 0.16 | 1.32 | 1.75 |
| Interest Coverage | -33.80 | 0.00 | 0.00 | -281.16 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -0.14 | 0.00 | 0.00 |
| Cash Conversion Cycle | -75,154.68 | -56,477.86 | 4,663.12 | 4,351.75 |